Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TEVA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or C… NCT05668013 · Crohn Disease, Colitis, Ulcerative TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Active, not recruiting | 247 | Jan 5, 2026 | Registry ↗ |
| Nov 5, 2026 | Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo NCT07920211 · Vitiligo TEV-53408 Dose A, TEV-53408 Dose B | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 2/3 | Not yet recruiting | 1,020 | Sep 12, 2030 | Registry ↗ |
| Nov 5, 2026 | A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy NCT06568237 · Multiple System Atrophy TEV-56286, Placebo | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Active, not recruiting | 349 | Sep 15, 2027 | Registry ↗ |
| Nov 4, 2026 | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propiona… NCT06664619 · Asthma Fp/ABS, FP | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Completed was active, not recruiting | 649 | Oct 26, 2026 | Registry ↗ |
| Nov 4, 2026 | A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effectiv… NCT06052267 · Asthma TEV-56248, Albuterol sulfate | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Active, not recruiting | 2,769 | Dec 31, 2026 | Registry ↗ |
| Nov 3, 2026 | Real-World Impact of TV-44749 in Adults With Schizophrenia NCT07913100 · Schizophrenia TV-44749 | TEVA Teva Branded Pharmaceutical Products R&D LLC | — | Not yet recruiting | 1,085 | May 31, 2031 | Registry ↗ |
| Oct 29, 2026 | A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo NCT06625177 · Vitiligo TEV-53408 | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Recruiting | 66 | Apr 26, 2028 | Registry ↗ |
| Oct 9, 2026 | An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy NCT07197866 · Multiple System Atrophy TEV-56286 | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Recruiting | 200 | May 3, 2029 | Registry ↗ |
| Oct 9, 2026 | A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease NCT06807463 · Celiac Disease TEV-53408, Placebo | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Active, not recruiting | 50 | Oct 2, 2026 | Registry ↗ |
| Oct 1, 2026 | A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis NCT04729621 · Osteoporosis, Postmenopausal TVB-009, Prolia® | TEVA Teva Pharmaceuticals USA | Phase 3 | Completed | 332 | Dec 31, 2022 | Registry ↗ |
| Sep 30, 2026 | Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The… NCT05617820 · Dyspareunia Estradiol, Imvexxy | TEVA Teva Pharmaceuticals USA | Phase 3 | Completed | 1,050 | Mar 15, 2024 | Registry ↗ |
| Sep 8, 2026 | A Trial to Assess TEV-56286 at Different Doses in Healthy Participants NCT07674940 · Healthy Volunteers TEV-56286, Placebo | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Recruiting | 69 | Jan 15, 2027 | Registry ↗ |
| Aug 27, 2026 | Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntingt… NCT07601516 · Huntington's Disease, Chorea Deutetrabenazine | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 4 | Completed | 50 | Oct 24, 2025 | Registry ↗ |
| Aug 7, 2026 | Mass Balance Clinical Trial With TEV-56286 NCT06627231 · Healthy Participants TEV-56286, [14C]-TEV-56286 | TEVA Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 | Completed | 8 | Nov 29, 2024 | Registry ↗ |
| Aug 4, 2026 | Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination W… NCT06290102 · Asthma TEV-56248, Fp MDPI | TEVA Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 | Completed | 30 | Oct 1, 2024 | Registry ↗ |
| Jul 27, 2026 | Fremanezumab Managed Access Program for Pediatric Patients NCT03539393 · Migraine Fremanezumab | TEVA Teva Branded Pharmaceutical Products R&D LLC | — | Available | — | — | Registry ↗ |
| Jul 24, 2026 | A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents NCT04530110 · Migraine Fremanezumab | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Completed | 499 | Aug 15, 2025 | Registry ↗ |
| Jun 30, 2026 | Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia NCT06253546 · Schizophrenia TV-44749 318mg, Oral Olanzapine 10mg/day | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | 24 | Jun 12, 2025 | Registry ↗ |
| Jun 22, 2026 | A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Ye… NCT04458857 · Migraine Fremanezumab, Placebo | TEVA Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | 235 | Mar 13, 2024 | Registry ↗ |
| Jun 4, 2026 | An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV… NCT06480552 · Advanced Solid Tumors TEV-56278, Pembrolizumab | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Recruiting | 240 | May 26, 2029 | Registry ↗ |
| Mar 27, 2026 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease NCT05499130 · Crohn Disease, Colitis, Ulcerative TEV-48574, Placebo | TEVA Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | Completed | 290 | Nov 12, 2024 | Registry ↗ |
| Mar 19, 2026 | A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler W… NCT03890666 · Asthma Albuterol eMDPI DS, albuterol | TEVA Teva Branded Pharmaceutical Products R&D, Inc. | Phase 4 | Completed | 333 | Oct 4, 2021 | Registry ↗ |
| Mar 17, 2026 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to… NCT05693935 · Schizophrenia TV-44749, Placebo | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Completed | 675 | Mar 19, 2024 | Registry ↗ |
| Feb 9, 2026 | A Study to Assess New Formulations of TEV-56286 NCT06911567 · Healthy Participants TEV-56286 Test, TEV-56286 Reference | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | 47 | May 22, 2025 | Registry ↗ |
| Jan 30, 2026 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple My… NCT05590377 · Multiple Myeloma Modakafusp Alfa, Daratumumab | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1/2 | Terminated | 15 | May 22, 2024 | Registry ↗ |
| Jan 29, 2026 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma NCT05556616 · Multiple Myeloma Modakafusp alfa, Lenalidomide | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Terminated | 15 | Jun 4, 2024 | Registry ↗ |
| Jan 29, 2026 | A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With… NCT04157517 · Neoplasms, Melanoma Modakafusp Alfa, Pembrolizumab | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1/2 | Terminated | 45 | Dec 20, 2023 | Registry ↗ |
| Jan 29, 2026 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma NCT03215030 · Multiple Myeloma Modakafusp alfa, Dexamethasone | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1/2 | Terminated | 272 | Jul 1, 2024 | Registry ↗ |
| Jan 26, 2026 | Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Particip… NCT06319170 · Schizophrenia, Schizoaffective Disorder Olanzapine Extended Release, Olanzapine Immediate Release | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | 106 | Jan 15, 2025 | Registry ↗ |
| Jan 14, 2026 | An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Par… NCT06315283 · Schizophrenia TV-44749, Oral olanzapine | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | 153 | Aug 14, 2025 | Registry ↗ |
| Jan 14, 2026 | A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combina… NCT04392648 · Relapsed and/or Refractory Multiple Myeloma TAK-573, Pomalidomide | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Withdrawn | 0 | Nov 10, 2023 | Registry ↗ |
| Dec 19, 2025 | A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17… NCT04464707 · Migraine Fremanezumab, Placebo | TEVA Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | 292 | Nov 29, 2024 | Registry ↗ |
| Dec 17, 2025 | Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psori… NCT06742957 · Plaque Type Psorisis Tapinarof Cream 1%, VTAMA® | TEVA Teva Pharmaceuticals USA | Phase 3 | Completed | 560 | Oct 7, 2025 | Registry ↗ |
| Nov 26, 2025 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safe… NCT05458011 · Migraine Fremanezumab, Placebo | TEVA Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | 365 | Jan 31, 2024 | Registry ↗ |
| Oct 7, 2025 | Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic I… NCT04976192 · Chronic Urticaria TEV-45779, XOLAIR® Injection | TEVA Teva Pharmaceuticals USA | Phase 3 | Completed | 608 | Apr 5, 2024 | Registry ↗ |
| Sep 26, 2024 | Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment O… NCT05550337 · Acne Vulgaris Trifarotene 0.005 % Topical Cream, AKLIEF® | TEVA Teva Pharmaceuticals USA | Phase 3 | Completed | 807 | May 9, 2023 | Registry ↗ |
| Sep 19, 2024 | Topiramate 25 mg Capsules Under Fasting Conditions NCT00905164 · Healthy Topiramate Capsules, 25 mg, Topamax® Capsules, 25 mg | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 24 | Jun 2002 | Registry ↗ |
| Sep 19, 2024 | Topiramate 25 mg Capsules Under Fed Conditions NCT00904943 · Healthy Topiramate Capsules, 25 mg, Topamax® Capsules, 25 mg | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 18 | Jul 2002 | Registry ↗ |
| Sep 19, 2024 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions NCT00834977 · Healthy Amlodipine-benazepril 10 mg-20 mg capsules, Lotrel® 10 mg-2… | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 48 | May 2004 | Registry ↗ |
| Sep 19, 2024 | Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions NCT00829426 · Healthy Alprazolam Extended-Release 3 mg Tablets, Alprazolam Extend… | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 32 | Jun 2005 | Registry ↗ |
| Aug 21, 2024 | Valacyclovir 1000 mg Tablet Under Fed Conditions NCT01149460 · Healthy Valacyclovir, Valacyclovir | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 36 | Sep 2004 | Registry ↗ |
| Aug 21, 2024 | Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions NCT00934921 · Healthy Ondansetron, Zofran® | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 24 | Feb 2003 | Registry ↗ |
| Aug 21, 2024 | Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions NCT00934180 · Healthy Ondansetron, Zofran® | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 24 | Dec 2002 | Registry ↗ |
| Aug 21, 2024 | Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions NCT00836901 · Healthy amoxicillin-clavulanic acid, Augmentin® | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 52 | Sep 2003 | Registry ↗ |
| Aug 21, 2024 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions NCT00835367 · Healthy Amlodipine-benazepril 10 mg-20 mg capsules, Lotrel® 10 mg-2… | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 68 | Mar 2004 | Registry ↗ |
| Aug 21, 2024 | Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions NCT00833521 · Healthy Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 38 | Feb 2002 | Registry ↗ |
| Aug 21, 2024 | Zaleplon 10mg Capsules Under Fasting Conditions NCT00829998 · Healthy Zaleplon 10 mg Capsules, Sonata® 10 mg Capsules | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 40 | Feb 2004 | Registry ↗ |
| Aug 21, 2024 | Zaleplon 10 mg Capsules Under Non-Fasting Conditions NCT00829868 · Healthy Zaleplon 10 mg Capsules, SONATA® 10 mg capsules | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 42 | Mar 2004 | Registry ↗ |
| Aug 20, 2024 | Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions NCT01149733 · Healthy Tamsulosin, Tamsulosin | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 32 | Nov 2004 | Registry ↗ |
| Aug 20, 2024 | Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Cond… NCT01149473 · Healthy Losartan potassium/Hydrochlorothiazide, Losartan potassium/… | TEVA Teva Pharmaceuticals USA | Phase 1 | Completed | 80 | Apr 2004 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances